Breast Cancer

Low cardiotoxicity risk with anti-HER2 agents shows treatment can continue

Cardiotoxicity related to treatment with anti-HER2 therapies is reassuringly low and resolution rates are high, allowing most patients to continue their breast cancer treatment, Australian research shows. A study of 287 patients with HER2 positive advanced breast cancer from the Australian TABITHA registry, found 6% of patients experienced mainly asymptomatic cardiotoxicity associated with anti-HER2 monotherapy ...

Already a member?

Login to keep reading.

© 2022 the limbic